Investigating how ubiquitination affects tau protein aggregation in Alzheimer's disease
The Role of Ubiquitination in Tau Oligomers Pathogenesis
['FUNDING_R01'] · UNIVERSITY OF TEXAS MED BR GALVESTON · NIH-11076802
This study is looking at how a process called ubiquitination affects the buildup of harmful tau proteins in the brain, which are linked to Alzheimer's disease, and aims to find new ways to stop these proteins from causing memory problems in patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TEXAS MED BR GALVESTON (nih funded) |
| Locations | 1 site (GALVESTON, UNITED STATES) |
| Trial ID | NIH-11076802 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of ubiquitination in the formation of tau oligomers, which are toxic aggregates associated with Alzheimer's disease. By examining how these tau aggregates evade degradation by the neuronal ubiquitin-proteasome system, the study aims to uncover mechanisms that contribute to cognitive decline in patients. The researchers will analyze unique post-translational modifications of tau oligomers to identify potential therapeutic targets. This work could lead to new strategies for halting the progression of Alzheimer's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those exhibiting early signs of cognitive decline.
Not a fit: Patients with other forms of dementia unrelated to tau pathology may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of therapies that effectively slow or halt the progression of Alzheimer's disease.
How similar studies have performed: Previous research has shown promising results in targeting tau pathology, indicating that this approach could lead to significant advancements in Alzheimer's treatment.
Where this research is happening
GALVESTON, UNITED STATES
- UNIVERSITY OF TEXAS MED BR GALVESTON — GALVESTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KAYED, RAKEZ — UNIVERSITY OF TEXAS MED BR GALVESTON
- Study coordinator: KAYED, RAKEZ
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome, Alzheimer's Disease